Oxidative stress and inflammatory markers in ovarian follicular fluid of women with diminished ovarian reserve during in vitro fertilization.


Journal

Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849

Informations de publication

Date de publication:
23 Oct 2023
Historique:
received: 11 07 2023
accepted: 02 10 2023
medline: 30 10 2023
pubmed: 24 10 2023
entrez: 23 10 2023
Statut: epublish

Résumé

Follicular microenvironment has been proposed as an important factor for oocyte grown and maturation. We sought to evaluate the oxidative stress and inflammatory levels in follicular fluid (FF) and association with embryo quality in patients with diminished ovarian reserve (DOR). The current research included 46 DOR cases and 56 normal ovarian reserve (NOR) cases. Twelve representative oxidative stress markers and eight representative inflammatory factors were measured in the FF. Oxidative stress markers total GSH (T-GSH) was decreased in the FF from women with DOR compared with that in NOR group (P = 0.041). More modest differences were observed for reduced GSH (rGSH) and rGSH/GSSG. Women with DOR compared to controls had higher level of TNF-α (P = 0.000) and lower level of IL-18 (P = 0.013). Correlation analysis revealed that GSSG was negatively correlated with normal fertilization rate in NOR group (r = -0.358, P = 0.008), and reduced GSH was negatively correlated with normal fertilization rate in DOR group (r = -0.299, P = 0.049). Moreover, as the regression analysis data showed, the GSSG level was significantly associated with embryo quality indicator. The FF in DOR patients was accompanied by increased oxidative stress and inflammatory levels. Follicular development of women with DOR might be influenced by unusual IL-18 and TNF-α levels in FF. And oxidative stress marker GSSG in NOR group was a negative predictor for embryo quality.

Sections du résumé

BACKGROUND BACKGROUND
Follicular microenvironment has been proposed as an important factor for oocyte grown and maturation. We sought to evaluate the oxidative stress and inflammatory levels in follicular fluid (FF) and association with embryo quality in patients with diminished ovarian reserve (DOR).
METHODS METHODS
The current research included 46 DOR cases and 56 normal ovarian reserve (NOR) cases. Twelve representative oxidative stress markers and eight representative inflammatory factors were measured in the FF.
RESULTS RESULTS
Oxidative stress markers total GSH (T-GSH) was decreased in the FF from women with DOR compared with that in NOR group (P = 0.041). More modest differences were observed for reduced GSH (rGSH) and rGSH/GSSG. Women with DOR compared to controls had higher level of TNF-α (P = 0.000) and lower level of IL-18 (P = 0.013). Correlation analysis revealed that GSSG was negatively correlated with normal fertilization rate in NOR group (r = -0.358, P = 0.008), and reduced GSH was negatively correlated with normal fertilization rate in DOR group (r = -0.299, P = 0.049). Moreover, as the regression analysis data showed, the GSSG level was significantly associated with embryo quality indicator.
CONCLUSIONS CONCLUSIONS
The FF in DOR patients was accompanied by increased oxidative stress and inflammatory levels. Follicular development of women with DOR might be influenced by unusual IL-18 and TNF-α levels in FF. And oxidative stress marker GSSG in NOR group was a negative predictor for embryo quality.

Identifiants

pubmed: 37872635
doi: 10.1186/s13048-023-01293-0
pii: 10.1186/s13048-023-01293-0
pmc: PMC10591385
doi:

Substances chimiques

Interleukin-18 0
Glutathione Disulfide ULW86O013H
Tumor Necrosis Factor-alpha 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

206

Subventions

Organisme : National Natural Science Foundation of China
ID : No. 82001574
Organisme : Special Fund for Family Planning of the Military Commission Logistics Department
ID : No20JSZ07

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Sci Adv. 2021 Jan 1;7(1):
pubmed: 33523841
J Ovarian Res. 2023 Apr 15;16(1):77
pubmed: 37061732
Exp Gerontol. 2014 Aug;56:154-63
pubmed: 24607549
Clin Chim Acta. 2023 Jan 1;538:29-35
pubmed: 36368351
Biol Reprod. 2022 Feb 22;106(2):351-365
pubmed: 34982142
Free Radic Biol Med. 2015 Sep;86:295-307
pubmed: 26057937
Fertil Steril. 2020 Jul;114(1):118-124.e1
pubmed: 32622406
Front Immunol. 2021 May 17;12:685724
pubmed: 34079559
Reprod Sci. 2022 Sep;29(9):2515-2524
pubmed: 34738218
Am J Reprod Immunol. 2001 Nov;46(5):349-57
pubmed: 11712764
Cytokine. 2017 Mar;91:180-186
pubmed: 28082237
Reproduction. 2013 Aug 21;146(4):389-95
pubmed: 23886995
Endocrine. 1999 Feb;10(1):19-23
pubmed: 10403567
Reprod Biol Endocrinol. 2014 Jul 06;12:60
pubmed: 24997727
Hum Reprod. 2011 Jul;26(7):1616-24
pubmed: 21505041
Reprod Biol. 2005 Mar;5(1):5-17
pubmed: 15821775
Theriogenology. 2011 Mar 15;75(5):867-76
pubmed: 21211832
Fertil Steril. 2022 Apr;117(4):655-656
pubmed: 35367010
Biochem Biophys Res Commun. 1989 Sep 15;163(2):1038-46
pubmed: 2551266
Fertil Steril. 2012 Jul;98(1):126-30
pubmed: 22578534
Reprod Biol Endocrinol. 2021 Sep 14;19(1):143
pubmed: 34521427
Int J Mol Sci. 2022 Oct 21;23(20):
pubmed: 36293552
J Cell Mol Med. 2021 Jan;25(2):1128-1139
pubmed: 33459528
Sci Rep. 2021 Jan 11;11(1):278
pubmed: 33432051
J Ovarian Res. 2017 Jul 12;10(1):44
pubmed: 28701210
Reprod Toxicol. 2013 Dec;42:116-24
pubmed: 23994512
J Assist Reprod Genet. 2021 Feb;38(2):471-477
pubmed: 33216309
Reproduction. 2021 Jul 14;162(2):R19-R33
pubmed: 33999842
J Immunol Res. 2019 Jan 2;2019:8069898
pubmed: 30719458
J Gynecol Obstet Hum Reprod. 2020 Apr;49(4):101704
pubmed: 32028036
J Assist Reprod Genet. 2015 Dec;32(12):1709-12
pubmed: 26463876
J Cell Physiol. 2021 Dec;236(12):7966-7983
pubmed: 34121193
Front Endocrinol (Lausanne). 2022 Feb 18;13:787876
pubmed: 35250857
Oxid Med Cell Longev. 2019 Oct 20;2019:5316984
pubmed: 31772706
Eur J Obstet Gynecol Reprod Biol. 2015 Jan;184:112-6
pubmed: 25498475
J Clin Endocrinol Metab. 2022 Jul 14;107(8):2307-2317
pubmed: 35521772

Auteurs

Yan Huang (Y)

Center of Reproductive Medicine, the General Hospital of Southern Theater Command, Guangzhou, 510010, China.

Yi Cheng (Y)

Center of Reproductive Medicine, the General Hospital of Southern Theater Command, Guangzhou, 510010, China.

Min Zhang (M)

Center of Reproductive Medicine, the General Hospital of Southern Theater Command, Guangzhou, 510010, China.

Yan Xia (Y)

Center of Reproductive Medicine, the General Hospital of Southern Theater Command, Guangzhou, 510010, China.

Xiaoyan Chen (X)

Center of Reproductive Medicine, the General Hospital of Southern Theater Command, Guangzhou, 510010, China.

Yexing Xian (Y)

Center of Reproductive Medicine, the General Hospital of Southern Theater Command, Guangzhou, 510010, China.

Dewei Lin (D)

Center of Reproductive Medicine, the General Hospital of Southern Theater Command, Guangzhou, 510010, China.

Suyan Xie (S)

Center of Reproductive Medicine, the General Hospital of Southern Theater Command, Guangzhou, 510010, China.

Xinyu Guo (X)

Center of Reproductive Medicine, the General Hospital of Southern Theater Command, Guangzhou, 510010, China. iris92@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH